Quantcast

Daily Traders Edge

5 Extremely Lucrative Biotech Stocks You Should Be Watching Now

September 14
10:23 2018

September is typically an ugly month for stocks. According to CNBC, on a 100-year basis, September is the only month that has a losing record. So take a break from market dynamics with these exciting biotech options. Biotech stocks march to a different tune. They can spike massively on positive news — be it key trial results or regulatory approvals. Of course, the opposite is also true and stocks can crash just as quickly on unexpected disappointments (delays, failed trials, regulatory rejection). With that in mind, we used TipRanks to ensure two crucial points: 1) big support from the Street (in fact, all these stocks have received only buy ratings in the last three months) and 2) eye-watering upside potential ahead. Now let’s see how the following hot stocks tick these two boxes:

Sorrento Therapeutics, Inc (NASDAQ:SRNE)

Sorrento is a clinical-stage biopharma developing new therapies to turn malignant cancers into manageable and possibly curable diseases. This includes everything from antibodies to pain management- including non-opioid pain medication ZTlido.

This medicated lidocaine plaster received FDA approval earlier this year and is now gearing up for launch. Top HC Wainwright analyst Ram Selvaraju (Profile & Recommendations) believes ZTlido “possesses best-in-class properties within the topical lidocaine niche.” He has a $40 price target on the stock- indicating massive upside potential of 647%!

The best part is that ZTlido uses far less lidocaine than in Lidoderm while efficacy is maintained due to improved adhesion and delivery. Overall, this ‘Strong Buy’ stock has a $21.67 average analyst price target (305%).

Continue Reading At Tip Ranks

Related Articles

Newsletter Signup

Sign up for our free newsletter